- Biogen shares plunge nearly 30% after ending trial for potential blockbuster Alzheimer’s drugCNBC
- Biogen halts study of Alzheimer’s drug, a blow to hopes for new treatmentSTAT
- Biogen’s Alzheimer’s drug aducanumab implodes in a PhIII disaster — wiping out $15B-plus in market capEndpoints News
- Biogen Shares Plunge After Alzheimer’s Drug SetbackBloomberg
- Biogen hit by ‘transformative failure’ as it cans adacanumab testsFierceBiotech
- View full coverage on Google News